223 related articles for article (PubMed ID: 37233785)
1. A prospective head-to-head comparison of [
Wang G; Li L; Zhu M; Zang J; Wang J; Wang R; Yan W; Zhu L; Kung HF; Zhu Z
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3126-3136. PubMed ID: 37233785
[TBL] [Abstract][Full Text] [Related]
2. Head-to-head comparison of [
Wang G; Hong H; Zang J; Liu Q; Jiang Y; Fan X; Zhu Z; Zhu L; Kung HF
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1052-1062. PubMed ID: 34557930
[TBL] [Abstract][Full Text] [Related]
3. Head-to-Head Comparison of 68 Ga-P16-093 and 68 Ga-PSMA-617 PET/CT in Patients With Primary Prostate Cancer : A Pilot Study.
Wang G; Li L; Zang J; Hong H; Zhu L; Kung HF; Zhu Z
Clin Nucl Med; 2023 Apr; 48(4):289-295. PubMed ID: 36727866
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Head-to-head comparison of [
Wang G; Li L; Wang J; Zang J; Chen J; Xiao Y; Fan X; Zhu L; Kung HF; Zhu Z
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1499-1509. PubMed ID: 36600099
[TBL] [Abstract][Full Text] [Related]
6. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
8. Comparison of parametric imaging and SUV imaging with [
Chen R; Ng YL; Yang X; Zhu Y; Li L; Zhao H; Zhou Y; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):568-580. PubMed ID: 37792025
[TBL] [Abstract][Full Text] [Related]
9. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
10. Determination of optimal
Wen J; Zhu Y; Li L; Liu J; Chen Y; Chen R
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2086-2095. PubMed ID: 34962583
[TBL] [Abstract][Full Text] [Related]
11. Head-to-Head Comparison of
Han T; Quan Z; Wang M; Meng X; Zhang M; Ye J; Li G; Wang J; Kang F
Mol Pharm; 2023 Nov; 20(11):5646-5654. PubMed ID: 37862042
[TBL] [Abstract][Full Text] [Related]
12. Prospective Evaluation of
Lopci E; Lughezzani G; Castello A; Saita A; Colombo P; Hurle R; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Casale P; Pietro D; Bevilacqua G; Balzarini L; Buffi NM; Guazzoni G; Lazzeri M
Eur Urol Focus; 2021 Jul; 7(4):764-771. PubMed ID: 32312701
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with
Kalshetty A; Menon B; Rakshit S; Bhattacharjee A; Basu S
J Nucl Med Technol; 2021 Sep; 49(3):235-240. PubMed ID: 34244223
[TBL] [Abstract][Full Text] [Related]
14. Comparison of
Schollhammer R; Robert G; Asselineau J; Yacoub M; Vimont D; Balamoutoff N; Bladou F; Bénard A; Hindié E; Gallerande HC; Morgat C
J Nucl Med; 2023 Mar; 64(3):379-385. PubMed ID: 36215569
[TBL] [Abstract][Full Text] [Related]
15. Preliminary Evaluation of
Lee H; Scheuermann JS; Young AJ; Doot RK; Daube-Witherspoon ME; Schubert EK; Fillare MA; Alexoff D; Karp JS; Kung HF; Pryma DA
Mol Imaging Biol; 2022 Oct; 24(5):710-720. PubMed ID: 35349040
[TBL] [Abstract][Full Text] [Related]
16. Tumor Sink Effect in
Gafita A; Wang H; Robertson A; Armstrong WR; Zaum R; Weber M; Yagubbayli F; Kratochwil C; Grogan TR; Nguyen K; Navarro F; Esfandiari R; Rauscher I; Menze B; Elashoff D; Delpassand ES; Herrmann K; Czernin J; Hofman MS; Calais J; Fendler WP; Eiber M
J Nucl Med; 2022 Feb; 63(2):226-232. PubMed ID: 34049987
[TBL] [Abstract][Full Text] [Related]
17. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
Demirci E; Sahin OE; Ocak M; Akovali B; Nematyazar J; Kabasakal L
Nucl Med Commun; 2016 Nov; 37(11):1169-79. PubMed ID: 27333090
[TBL] [Abstract][Full Text] [Related]
18. Assessing dynamic metabolic heterogeneity in prostate cancer patients via total-body [
Chen R; Ng YL; Yang X; Zhu Y; Li L; Zhao H; Huang G; Liu J
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):896-906. PubMed ID: 37889299
[TBL] [Abstract][Full Text] [Related]
19. Head-to-Head Comparison of
Kuten J; Fahoum I; Savin Z; Shamni O; Gitstein G; Hershkovitz D; Mabjeesh NJ; Yossepowitch O; Mishani E; Even-Sapir E
J Nucl Med; 2020 Apr; 61(4):527-532. PubMed ID: 31562225
[No Abstract] [Full Text] [Related]
20. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
